Dmytro Kharkov

Ocugen, Inc. shares clinical trial journey of OCU400 participant in fight against retinitis pigmentosa

Ocugen, Inc. shares clinical trial journey of OCU400 participant in fight against retinitis pigmentosa
Ocugen, Inc. details OCU400 trial

Ocugen, Inc. has featured the personal account of Manny, an OCU400 clinical trial participant, in the latest story from Fighting Blindness.

Manny describes how living with retinitis pigmentosa has shaped his perspective and explains the role of ongoing research in offering renewed hope to affected individuals. Ocugen, Inc. continues to advance clinical studies aimed at tackling rare inherited eye diseases, with the OCU400 trial representing a step forward in gene therapy research within the biotechnology sector.

Ocugen, Inc. previously developed modifier gene therapies aimed at rare genetic retinal diseases, focusing on preserving vision as detailed in an earlier company update. The firm has also explored new approaches for gene delivery in brain-targeted therapies, addressing breakthroughs and barriers in central nervous system disorders, according to another recent report. These initiatives reflect Ocugen's broader activity in the gene therapy sector.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.